

LEELA PALACES HOTELS & RESORTS LIMITED

(formerly known as Schloss Bangalore Limited)

(formerly known as Schloss Bangalore Private Limited)

Registered Office: The Leela Palace, Diplomatic Enclave, Africa Avenue, Netaji Nagar New Delhi South Delhi 110023
Tel No. +91 (11) 39331234 Email Id: cs@theleela.com CIN: L55209DL2019PLC347492 Website: www.theleela.com

Ref No.: THELEELA/2025-26/067

Date: January 10, 2026

| To | To |
|---|--|
| <p>Sr. General Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 Scrip Code- 544408 ISIN - INE0AQ201015</p> | <p>Sr. General Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051 Symbol- THELEELA ISIN - INE0AQ201015</p> |

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Para B Part A to Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Schloss Chanakya Private Limited (SCPL), a material subsidiary of the Leela Palaces Hotels & Resorts Limited (“Company”) has received a favourable order from the Office of the Assistant Commissioner of Income Tax, Transfer Pricing, Delhi for the Assessment Year (AY) 2023-24, issued under Section 92CA(3) of Income-tax Act, 1961, in respect of determination of the Arm’s Length Price for certain international transactions entered into by SCPL during FY 2022-23.

We wish to further inform that The Transfer Pricing Officer has concluded that **no adverse inference** is required in respect of the international transactions undertaken by the SCPL. Accordingly, no transfer pricing adjustment has been proposed pursuant to the said order.

The required information, in compliance with Para B of Part A of Schedule III to the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (collectively, “Relevant Laws”), is enclosed herewith as **Annexure – A**.

The above information will also be available on the website of the Company at www.theleela.com/investors.

We request you to kindly take the above on record.

Thanking you,

For Leela Palaces Hotels & Resorts Limited

(formerly known as Schloss Bangalore Limited)

(formerly known as Schloss Bangalore Private Limited)

Jyoti Maheshwari

Company Secretary and Compliance Officer

Membership No.: A24469

Encl.: as Above

LEELA PALACES HOTELS & RESORTS LIMITED

(formerly known as Schloss Bangalore Limited)

(formerly known as Schloss Bangalore Private Limited)

Registered Office: The Leela Palace, Diplomatic Enclave, Africa Avenue, Netaji Nagar New Delhi South Delhi 110023
Tel No. +91 (11) 39331234 Email Id: cs@theleela.com CIN: L55209DL2019PLC347492 Website: www.theleela.com

Annexure – A

Details as required in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

| Sr. No. | Particulars | Details |
|---------|---|--|
| 1 | Details of such settlement | The Assistant Commissioner of Income Tax, Transfer Pricing, Delhi has passed an order under Section 92CA(3) of the Income-tax Act, 1961 for the Assessment Year 2023–24 determining the Arm’s Length Price in respect of the international transactions entered into by the SCPL during FY 2022–23. |
| 2 | Terms of the settlement | After examination of the transfer pricing documentation and submissions made by the SCPL, the Transfer Pricing Officer has concluded that no adverse inference is required to be drawn in respect of the international transactions undertaken by the SCPL during the relevant financial year. Accordingly, no transfer pricing adjustment has been proposed pursuant to the said order. |
| 3 | Compensation/penalty paid (if any) | Not applicable. |
| 4 | Impact of such settlement on the financial position of the listed entity. | The order does not contain any adverse findings and is in favour of SCPL; accordingly, it does not have any adverse financial impact on the Company. |